Neuren is significant undervalued ..
Neuren Pharma ( NEU.AX)
Marketcap: only 48 million A$
Price: 0,34 A$
Awesome Pipeline :
Glypromate MCI in CABG Phase 3 ongoing
NNZ-2566 Severe TBI (traumatic brain injury) Phase 2a (deal with US Army)
NNZ-2566 Mild/Mod TBI Phase 2
Motiva Apathy Phase 2b
Taylor Collison
http://preset.sphilo.com/neuren/images/NEU%200708%20-%20Hamilton.pdf
By the end 1Q CY08, we expect Neuren to be running four major
efficacy trials; namely three Phase 2 trials for NNZ-2566 in
mild/moderate and severe TBI and Motiva™ in post stroke abulia/
depression coupled with the current Phase 3 trial for Glypromate® in
CABG. All indications potentially provide Neuren with first to market,
billion dollar opportunities. With a current market cap of $40.2m, Neuren
remains a solid value proposition in the sector, where FDA INDs for mid
to late stage clinical trials continues to remain a vexing proposition. We
maintain our Speculative Buy recommendation and price target of $1.30,
though expect to make changes to our valuation model once the
acquisition has closed, which we expect during the current Q.
- Forums
- ASX - By Stock
- cheapest biotech stock on the asx
Neuren is significant undervalued ..Neuren Pharma (...
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.3¢ |
Change
-0.003(3.49%) |
Mkt cap ! $74.82M |
Open | High | Low | Value | Volume |
8.8¢ | 8.8¢ | 8.2¢ | $46.49K | 549.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 11758 | 8.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.4¢ | 24250 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 11758 | 0.083 |
1 | 36828 | 0.082 |
1 | 104000 | 0.081 |
4 | 217800 | 0.080 |
2 | 212658 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.084 | 24250 | 1 |
0.086 | 6100 | 1 |
0.087 | 65719 | 1 |
0.088 | 156793 | 6 |
0.089 | 135000 | 2 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online